Genmab — November 2017
-
@stockbull : 8,6% ÅTD, så hvis du mener "kun 20 %", skal der snart ske noget....
-
Stok Bull: Jeg skriver jo heller ikke at det er verdens undergang, at aktien ikke stiger p.t. (Men falder).....jeg forsøger bare at forklare de chatter, der vil snakke den op, at det kan man heldigvis ikke. Der skal resultater på bordet.... den har jo været snakket op i 2017, så realismen har heldigvis fået den på plads !
-
-
ISS?
-
Investigator initiated studies (IIS) are clinical studies initiated and managed by a non-pharmaceutical company researchers, like individual investigators, institutions, collaborative study groups or cooperative groups. The researcher is responsible for the legal and regulatory responsibilities of the trial sponsor for the conduct and management of the study as defined by all applicable laws and regulations.
-
Abstract 739 viser at Drd er markant bedre end dr og .......This updated analysis reveals that DRd continues to demonstrate a significant PFS benefit compared with Rd alone, and pt responses continue to deepen with DRd with longer follow up. Pts who receive DRd demonstrated longer time to next therapy and responded more favorably to subsequent therapy as evidenced by prolonged PFS2, suggesting that patients continue to observe clinical benefit from prior daratumumab treatment. Importantly, the
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind